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More than 1,700 somatic mutations in protein-coding re-
gions of the genome have been found in colorectal cancer 
(CRC) patient tumors and metastases, with an average of 
80–90 single-nucleotide variants (SNVs), which largely dif-
fer among individual patients (Wood et al., 2007). Only ∼32 
genes are recurrently mutated in tumors from different CRC 
patients, but a low incidence rate does not preclude func-
tional relevance of a gene mutation (Cancer Genome Atlas 
Network, 2012). The acquisition of multiple genetic lesions 
in protooncogenes and tumor suppressors drives the dom-
inating clones during cancer development (Nowell, 1976; 
Fearon and Vogelstein, 1990). Importantly, this does not occur 
in a fully linear order but in a branched, evolutionary process, 
resulting in multiple coexisting clones (Gerlinger et al., 2012; 
Landau et al., 2013; Siravegna et al., 2015).
Besides their genetic heterogeneity, cells within indi-
vidual tumors can differ functionally. CRC progression and 
metastasis formation are driven by tumorigenic cells that are 
able to generate tumors in immune-deficient mice and are 
thought to underlie tumor progression, relapse, and spread-
ing (O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Dieter 
et al., 2011; Merlos-Suárez et al., 2011). These tumorigenic 
cells share characteristics with normal intestinal epithelial 
stem cells, including high self-renewal and multilineage dif-
ferentiation capacity, and can be enriched as spheroids (Ver-
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meulen et al., 2008). Genetic marking allows measurement 
of clonal output from individual tumor cells after transplan-
tation of a mixture of tumorigenic and nontumorigenic cells 
because the exact integration site is unique to each trans-
duced cell. As clonal behavior of single tumor cells in total 
isolation cannot be predicted, we termed tumorigenic cells 
that give rise to uniquely marked clones as tumor clone–ini-
tiating cells (TcICs). Using TcICs as a surrogate to measure 
the self-renewal and tumor-forming capacity of cell mix-
tures without single-cell isolation, it has been shown that, 
like the normal epithelial regenerative compartment, the 
tumorigenic CRC cell compartment itself is functionally 
heterogeneous and contains distinct subfractions, which dif-
fer in self-renewal capacity and activation kinetics. Highly 
self-renewing, long-term, active cells on top of a cellular 
hierarchy drive long-term disease progression and metasta-
sis formation, whereas tumor-transient amplifying cells dis-
play limited self-renewal potential, and delayed contributing 
self-renewing cells contribute solely to tumor formation in 
secondary or tertiary mice (Dieter et al., 2011). Whether that 
functional heterogeneity is based on the presence of geneti-
cally distinct subclones is unclear.
To understand whether multiple, distinct genomic sub-
clones with TcIC activity exist within individual tumors and 
whether genetic subclones determine the functional hetero-
geneity of CRC TcICs, in this study, we combined ultradeep 
whole-genome sequencing of primary patient tumors and 
derived serially transplanted xenografts and parallel spheroid 
cultures with secondary genetic marking.
reSuLtS
Genetic makeup of patient tumors as well as derived 
spheroids and xenografts
To address whether the TcIC compartment in human CRC 
is genetically heterogeneous, we established spheroid cul-
tures from three CRC patient tumors (P1-TU, P2-TU, and 
P3-TU), as previously described (Dieter et al., 2011). Spher-
oid cultures are the most widely used model for enriching 
tumorigenic cells from primary, patient-derived cancer spec-
imens without the need for cell-surface marker-based sorting 
strategies (Singh et al., 2004; Fang et al., 2005; Lee et al., 2006; 
Hermann et al., 2007; O’Brien et al., 2007; Ricci-Vitiani et 
al., 2007; Todaro et al., 2007; Vermeulen et al., 2008; Dieter 
et al., 2011; Merlos-Suárez et al., 2011). Early passage spher-
oid cells derived from each patient were transplanted into 
immune-deficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) 
mice and were serially retransplanted for three generations. 
In parallel, spheroids were cultivated for the duration of the 
serial xenotransplantations and were harvested simultaneously 
with each xenograft generation (Fig. 1 A).
We first assessed the mutational landscape of primary 
patient tumors by high-coverage whole-genome sequencing 
(WGS; 110–126-fold; Fig. 1). We detected 23,121 SNVs, in-
cluding synonymous and nonsynonymous SNVs in P2-TU 
and 22,830 in P3-TU. In P1-TU, the absolute number of 
SNVs was roughly 10-fold higher (232,387), translating into 
a mutation rate of 100 SNVs per Mbp and reflecting the 
clinical diagnosis of MLH1-driven Lynch syndrome with an 
associated microsatellite instability–high (MSI-H) genotype 
(Fig. 1 B). As expected, in all patients, most SNVs (95–97%) 
were located in noncoding areas of the genome (Fig. 1 C). 
Although P1-TU and P2-TU displayed diploid baseline copy 
numbers, P3-TU contained a triploid genome. In line with 
the MSI-H phenotype, P1-TU contained only few copy 
number alterations (CNAs). P2-TU and P3-TU comprised 
multiple CNAs, leading to their classification as chromosom-
ally instable (CIN) tumors (Fig. 1 D).
Next, we assessed whether the genetic makeup of 
primary CRCs was maintained in spheroids and xenografts. 
Subsequently, all samples (early “S1” and late “S2” spheroids; 
early “X1” and late “X2” xenografts from the first and third 
xenograft generation, respectively) were sequenced genome 
wide with high coverage (102–120×). A large fraction of 
SNV was shared among all samples from an individual patient 
(P1 :63%, P2 :44%, and P3 :61%). However, 37–56% of SNVs 
were found only in a subset of each patient’s samples or solely 
in individual samples (Fig. 1 E). The copy number profiles of 
spheroids and xenografts indicated the same base ploidies as 
the respective primary tumors, with a largely stable genome 
for all samples derived from P1 and highly chromosomally 
unstable genomes in P2- and P3-derived samples (Fig.  1, 
F–H). Together, WGS revealed that, although spheroid 
cultures and xenografts faithfully reflected the general tumor 
genomic makeup, differences in the individual mutations 
were present in each sample.
Genomic subclones are highly dynamic in 
spheroids and xenografts
Throughout this article, the operational term “growth clone” 
is used to describe a cluster of genomic alterations, i.e., SNV 
or CNA, with analogous dynamics over time, as defined by 
their relative contribution within serial sample sets, whereas 
“genomic subclone” defines cells carrying identical genetic 
aberrations, i.e., SNVs and CNAs.
In summary, we first used SNVs and CNAs to define 
“growth clones” with analogous dynamics over time (Fig. 2). 
For each growth clone, we then calculated the cellular frac-
tion (CF). In a second step, we combined SNV and CNA 
growth clones, based on their CF, by applying combinator-
ics and maximum parsimony. This strategy allowed us to set 
up a model comprising the minimum number of genomic 
clones, defined as cells carrying identical genetic aberrations, 
which had to be present in each sample to explain the pro-
found-growth clone kinetics.
To identify SNV-based growth clones, the CF of SNVs 
was calculated (Materials and methods). Clusters of SNVs 
with similar CF dynamics over time were detected in all 
three patients (Fig. 2 A). SNVs contained in the main pop-
ulation represent fully clonal mutations, including alterations 
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Figure 1. Genetic makeup of primary crcs, derived xenografts, and spheroids. (A) High-coverage WGS of primary CRC tissue (TU; n = 3 patients), 
derived serial xenografts (n = 6; 2 serial mice/patient), and parallel spheroids (n = 6; 2 serial passages/patient). (B) Number of SNVs in three primary tumors. 
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such as APC and CTN NB1 (P1-main), KRAS (P1-main 
and P2-main), and TP53 (P1-main, P2-main, and P3-main; 
Table S1). Interestingly, for each patient, we detected three to 
five distinct subclonal SNV populations containing between 
226 and 18,158 individual SNVs distributed throughout the 
entire genome (Fig. 2 A, Table 1, and Fig. S1). Importantly, 
for most growth clones, the CFs, i.e., the corrected allele fre-
quencies, were not stable but changed dynamically over time 
during serial in vitro and in vivo passaging. Distinct growth 
clones were present at low CFs in S1 and grew out during 
long-term in vitro culture (e.g., P1-q3, P1-q5, and P3-q3), 
including SNVs in the coding regions of genes involved in 
deficient DNA mismatch repair (MMR), e.g., LIG1 (P1-q5). 
Other growth clones profoundly grew out during xenograft-
ing (e.g., P1-q1, P1-q2, P2-q1, P2-q2, and P3-q1; Fig. 2 A), 
including SNVs located in coding regions of MMR-related 
genes, e.g., ABL1 (P1-q1), CSDE1, and GLC CI1 (P1-q2), as 
well as the coding regions of commonly mutated genes in 
CRC, such as APC (P3-q1; Table S1).
In addition to SNVs, we used CNAs to identify growth 
clones. Although the majority of CNAs were clonal (1n, 
2n, 3n, etc.), subclonal CNAs with noninteger copy num-
bers could be identified in all patients (Fig. 1 D, right; and 
Fig. 2 B). In the next step, CFs were calculated for 25 non-
integer CNA segments from the total copy number (TCN) 
and grouped into 13 CNA-based growth clones, according to 
concordant clonal dynamics (P1:1, P2:6, and P3:6; Materials 
and methods). Similar to SNV-based growth clones, the CFs 
of CNA-based growth clones were not stable in serial passag-
ing but showed highly dynamic kinetics in serial xenografts 
and spheroids (Fig. 2 B and Table 1).
Next, we combined SNV- and CNA-based growth 
clones, applying combinatorics and maximum parsimony 
to define the minimum number of genomic subclones that 
had to be present in each sample to explain the profound 
growth-clone kinetics (Fig. 3, Table 1, and Fig. S2; Materials 
and methods). This strategy revealed that all primary tumors 
contained at least two coexisting genomic subclones. Fur-
thermore, genomic-subclone heterogeneity was detectable in 
S1 with at least three coexisting genomic subclones. Tumor 
initiation in X1 was driven by a minimum of three to four 
coexisting genomic subclones. In addition, multiple genomic 
subclones were present in X2, demonstrating that long-term 
tumor formation was driven by coexisting genomic sub-
clones. Interestingly, although the majority of genomic 
subclones identified in X2 already contributed to X1, their 
relative contribution changed substantially. Distinct genomic 
subclones grew out, whereas other genomic subclones even-
tually decreased or even vanished. Similarly, long-term spher-
oid cultivation resulted in outgrowth and loss of genomic 
subclones. Strikingly, within individual patients, completely 
different genomic subclones grew out and became dominant 
in vitro or in vivo. In summary, subclone combinatorics re-
vealed that primary patient tumors, spheroids, and xenografts 
comprised multiple, coexisting genomic subclones. Those 
subclones were not static but displayed substantial dynamic 
fluctuation, with different genomic subclones dominating the 
xenografts and spheroids of the same patient.
Genomic subclones harbor distinct mutational signatures
Mutational processes leave mutational signatures in the ge-
nome, which are characterized by specific nucleotide ex-
changes in the motif context of given SNVs (Alexandrov et 
al., 2013). In the main SNV population of all patients, strat-
ified signature analysis identified a clocklike, spontaneous 
deamination signature, which represents mutations accumu-
lated in a common ancestor before malignant transformation 
(Alexandrov et al., 2015). Other signatures in the main pop-
ulations were associated with deficient MMR (P1 and P3), 
double-strand break (DSB) repair (P2 and P3) or the APO 
BEC family (P3; Fig.  2  C and Fig. S3). Although most of 
these signatures were also detectable in corresponding growth 
clones, the relative contribution of the signatures differed sig-
nificantly among growth clones. Strikingly, within an individ-
ual growth clone, the relative contribution of a given signature 
remained stable during serial in vivo and in vitro passaging, 
thereby strongly supporting our strategy of genomic subclone 
definition. Likewise, we found that individual growth clones 
harbored private mutations in genes commonly affected in 
CRC or involved in MMR and DSB repair (Table S1). It is 
tempting to speculate that such mutations may have driven 
development of individual genomic subclones; however, that 
question needs to be addressed in future studies. In summary, 
mutational signature analysis strongly supported the presence 
of distinct genomic subclones with different mutational sig-
natures present in serial xenografts and spheroids.
Functional heterogeneity is maintained despite highly 
variable genomic-subclone contribution
We have shown before that the tumorigenic cell compart-
ment in CRC is hierarchically organized and comprises 
three distinct classes of cells driving tumor formation in 
vivo (Dieter et al., 2011): (1) long term active cells with a 
high self-renewal capability that rebuild tumors after serial 
transplantation, (2) tumor-transient amplifying cells with no 
detectable self-renewal potential that only transiently con-
tribute to tumor formation, and (3) delayed contributing, 
self-renewing tumorigenic cells that do not substantially drive 
losses (red). (Bottom left) Raw BAF. (Right) Segments harboring noninteger copy numbers. X axis, genomic location; y axis, copy numbers; light-blue lines, 
allele-specific copy numbers; dark-blue lines, total copy number; Chrom, chromosome; Mbp, mega base pair. (E) Concordance and discordance of SNVs in 
serial patient-derived samples. X-axis, number of SNVs. (F–H) Copy number profiles of patient-derived xenografts and spheroid cultures from P1 (F), P2 (G), 
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primary tumor growth but are recruited to tumor forma-
tion after serial transplantation. To test whether this functional 
heterogeneity is driven by genetic differences of distinct ge-
nomic subclones, we assessed the contribution of these func-
tionally heterogeneous cell fractions during early and late 
serial xenografting by secondary genetic marking (Fig.  4). 
Therefore, representative cell aliquots from sequenced X1 and 
X2 xenografts were transduced with an integrating lentiviral 
vector and serially transplanted for three successive genera-
tions. Because the vector semirandomly integrates into the 
genome, each transduced cell harbors a unique integration 
site (IS), which is stably passed onto daughter cells. Conse-
quently, the ISs can be used as individual molecular barcodes 
for initially transduced clones (Dieter et al., 2011). Because 
we could not predict the clonal behavior of single cells in 
complete isolation, we assessed tumorigenic cells giving rise 
to uniquely marked clones (TcICs) within tumors as sur-
rogates. After tumor formation, genetically marked tumors 
were harvested and used for highly sensitive linear amplifi-
cation–mediated PCR (LAM-PCR), followed by amplicon 
sequencing. IS analysis allowed a determination of the con-
tribution of each individual transduced (TcIC) clone in se-
rial transplants (Fig. 4 A). Interestingly, all samples contained 
multiple ISs (Fig.  4, B–D). The absolute number of ISs in 
individual, transduced xenografts from each patient reflected 
the cellular-transduction rate (Fig. 4 E). The clonal dynamics 
of marked TcIC clones in serial transplantation demonstrated 
that, in all three patients, highly proliferative, self-renewing 
cells; transiently active cells; and delayed contributing cells 
were present in the early xenografts (X1), demonstrating their 
hierarchical organization. Strikingly, we detected similar con-
tributions of the different subtypes to the marked serial xe-
nografts derived from late-passage xenografts (X2; Fig. 4 F). 
Although the relative proportion eventually differed among 
different patients, the content and functional heterogeneity 
within the TcICs were maintained in serial xenografts from 
Figure 2. Patient tumors, spheroids, and 
xenografts harbor distinct SnV- and cnV- 
based growth clones. (A) Each panel shows a 
pairwise comparison of CFs of the SNVs. Each 
dot represents one SNV. SNVs with similar 
kinetics over time were assigned to the same 
growth clone, colored accordingly, and either 
assigned to the main SNV-based growth 
clone (main; gray color), which is present 
in all cells, or to SNV-based growth clones, 
which are present in only a fraction of cells 
(q1-qx; colors as indicated). X and y axes, CF. 
(B) Representative chromosomal segments 
harboring subclonal copy numbers. Each small 
vertical panel shows the allele-specific copy 
number (light-blue line) and TCN (dark-blue 
line) for the chromosomal region indicated 
in the gray box above for one sample. 
Chrom, chromosome; Mbp, mega base pair. 
(C) Representative mutational profiles for 
growth clones of P1-X1. Each panel shows 
the relative signature exposures of one 
SNV-based growth clone. AC, Alexandrov COS 
MIC (nomenclature referring to http ://cancer 
.sanger .ac .uk /cosmic /signatures (Alexandrov et 
al., 2013); Chrom, chromosome. See also Figs. 
S1 and S3 and Table S1. (A–C) Experiments 
were performed independently with tumor 
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the same patient, despite profound, near-complete changes 
in the genomic subclone contribution (Fig. 4 G). These data 
strongly indicate that functional TcIC hierarchies were pres-
ent within at least multiple genomic subclones and were not 
caused by differences in the genetic mutations driving dif-
ferent genomic subclones.
dIScuSSIon
The functional heterogeneity of individual tumors is well 
established in human CRCs, with a tumorigenic cell frac-
tion with stem-like properties, i.e., self-renewal and dif-
ferentiation capacity, driving disease progression in serial 
transplantation models (O’Brien et al., 2007; Ricci-Vitiani 
Table 1. cFs of SnV- and cnA-based growth clones
Patient Growth clone No. SNVs Chrom Position TCN CF
TU S1 S2 X1 X2
P1 Mbp % % % % %
main 194.680 na na na 105 100 100 100 100
P1-q1 2.937 na na na 40 45 0 45 65
P1-q2 18.158 na na na 0 5 0 15 60
P1-q3 5.640 na na na 15 20 95 20 25
P1-q4 226 na na na 35 40 0 30 0
P1-q5 15.353 na na na 0 0 90 0 0
P1-c1 na X 1-155 1n 0 10 0 40 10
P2
main 14.875 na na na 95 100 100 100 100
P2-q1 796 na na na 0 10 10 45 90
P2-q2 1.174 na na na 0 0 0 0 60
P2-q3 3.106 na na na 0 15 20 10 0
P2-c1 raw na 5 63-69 3 n 0 70 40 30 10
P2-c1 raw na 5 71-180.5 3 n 0 70 40 30 10
P2-c1 raw na 7 62-70.5 3 n 10 60 40 20 0
P2-c1 raw na 7 70.5-88.5 3 n 0 70 40 30 0
P2-c1 combined na 5 and 7 na na 0 70 40 30 ≤10
P2-c2 raw na 7 90.5-117.5 3 n 100 60 50 30 0
P2-c2 raw na 7 117.5-159 4 n 100 60 40 30 0
P2-c2 combined na 7 na na 100 60 40-50 30 0
P2-c3 raw na 18 26.5-36.5 1 n 100 10 10 40 80
P2-c3 raw na 18 38.5-43 1 n 100 20 20 50 90
P2-c3 raw na 18 48.5-78 1 n 100 10 10 40 90
P2-c3 combined na 18 na na 100 10 10 40 90
P2-c4 raw na 3 95-102.5 4 n 0 10 0 10 60
P2-c4 raw na 3 105-175.5 4 n 0 0 0 10 60
P2-c4 raw na 3 175.5-198 5 n 0 0 0 0 70
P2-c4 combined na 3 na na 0 0 0 10 60
P2-c5 na 8 68-131.5 5 n 40 0 0 0 0
P2-c6 na 22 17.5-20 3 n 50 0 0 0 0
P3
main 13.625 na 13.625 na 100 100 100 100 100
P3-q1 608 na 608 na 0 10 0 15 85
P3-q2 343 na 343 na 0 55 95 55 10
P3-q3 390 na 390 na 0 0 65 0 0
P3-c1 raw na 3 1-7 4 n 30 0 0 0 0
P3-c1 raw na 3 13-29 4 n 20 0 0 0 0
P3-c1 raw na 3 29.5-33.5 4 n 20 0 0 0 0
P3-c1 raw na 3 52.5-61 4 n 30 0 0 0 0
P3-c1 combined na 3 na na 20-30 0 0 0 0
P3-c2 na 3 7-13 4 n 50 0 0 0 0
P3-c3 raw na 3 40.5-51.4 4 n 30 10 0 10 10
P3-c3 raw na 3 66.5-75.5 4 n 30 0 0 10 10
P3-c3 combined na 3 na na 30 ≤10 0 10 10
P3-c4 na 3 61-66.5 4 n 70 70 90 50 20
P3-c5 na 16 53.5-56 2 n 100 30 0 10 0
P3-c6 na 10 75-79 3 n 10 0 60 0 0
All noninteger CNA segments included are ≥2.5 Mbp, harbor maximal one noninteger allele, and have a minimum deviation of 30% from both contributing copy numbers in at least one 
sample (TU, S1, S2, X1, or X2). Breakpoints were rounded to the nearest 0.5 Mbp. Individual “raw” CNA segments were “combined” to CNA-based growth clones. Cellular fractions of raw CNA 
segments and CNA-based growth clones were rounded to the nearest 10%, cellular fractions of SNV-based growth clones to the neatest 5%. All experiments were performed independently 
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et al., 2007). Moreover, others and we have shown that this 
tumorigenic cell compartment itself is functionally heteroge-
neous with distinct subclasses differing in their self-renewal 
and metastasis-forming capacity (Dieter et al., 2011; Kreso et 
al., 2013). Apart from functional differences, coexisting ge-
netic subclones in individual patient tumors have been de-
scribed in many cancers (Anderson et al., 2011; Gerlinger 
et al., 2012; Landau et al., 2013). However, it remained an 
unsolved question whether functional tumor heterogeneity 
was based on fixed, differing genetic makeups that conferred 
functional consequences to subclones, i.e., self-renewal and 
tumor-initiating capacity.
We demonstrate in this study that distinct genomic sub-
clones are present in CRC primary tumors, xenografts, and 
spheroids. Assessing the relative contribution of tumor-cell 
classes differing in their tumor-forming and self-renewal 
capacity, as described before (Dieter et al., 2011), revealed 
that the functional heterogeneity was stable even after three 
rounds of serial transplantation. Self-renewing, long-term ac-
tive tumorigenic cells were not enriched, demonstrating that 
serially xenotransplanted tumors were not formed by highly 
proliferative clones without functional heterogeneity. At the 
same time, profound changes in genomic subclone contri-
bution resulted in almost complete changes of the subclonal 
repertoire in these tumor models. These findings strongly 
indicate that all individual genomic subclones are organized 
in a functional hierarchy, giving rise to all distinct “private” 
subtypes of self-renewing tumorigenic cells during serial xe-
notransplantation. One could speculate that the sequential 
addition of further relevant mutations to existing genomic 
subclones could alter the functional heterogeneity of affected 
clones. Although, in different patients, the neoplastic process 
is fueled by different sets of driver mutations, the malignant 
stem-cell compartment in colon cancer consists of hierar-
chical cell classes with crucial differences in self-renewal and 
metastatic potential, whose occurrence and kinetics cannot 
be explained by a stochastic contribution (Dieter et al., 2011). 
By using concordant dynamics of large numbers of SNVs 
and CNVs to identify genomic subclones, our study did not 
find any evidence that sequential accumulation of mutations 
determines subclone dynamics during the time span of serial 
transplantation. Of note, the identified subclones preexisted at 
the time of tumor resection and did not freshly occur during 
serial in vitro and in vivo passaging because they were defined 
by large numbers of independent mutations, thereby preclud-
ing conclusions regarding the initial transformation process.
Earlier studies using targeted or exome sequencing and 
SNV genotyping alone or in combination reported stable 
genetics in serial xenotransplantation and functional hetero-
geneity in genomically stable, single-cell–derived tumor xe-
nografts (Julien et al., 2012; Kreso et al., 2013; Bossi et al., 
2016). Our results indicate that, in those studies, the inter-
clonal dynamics were largely underestimated because of the 
lower sensitivity for genomic subclone detection. In contrast, 
more-sensitive WGS revealed highly dynamic genomic sub-
clones in xenografts and spheroid cultures. Tracing clonal 
Figure 3. Genomic subclone kinetics in serial in vivo and in vitro passaging. (A) Ancestral trees of identified genomic subclones in patient tumors, 
early spheroids, and serial xenografts. (B) Relative contribution of genomic subclones from A in each sample. (C) Relative contribution of genomic subclones 
in patient tumors and serial spheroids. (D) Ancestral trees for genomic subclones shown in (C). Colors, defined genomic subclones; light gray, unidentified 
genomic subclones; gray circles, common ancestors; dashed lines, phylogeny constructed applying maximum parsimony. See also Fig. S2. (A–D) Experiments 
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dynamics demonstrates that, in competitive environments, 
multiple, coexisting genomic subclones within individual pa-
tient-derived xenografts fuel long-term tumor initiation, sug-
gesting that the long-term tumor-initiating capacity is a basic 
characteristic of several genomic subclones and not restricted 
to a specific clone within an individual tumor.
We would like to emphasize that all genomic subclones 
derive from a common ancestor and are, thereby, of clonal or-
igin by definition. The additional genetic variation generated 
by accumulation of mutations during further progression en-
ables robust identification of genomic subclones. Sequencing 
coverage of >100 times and applying a minimalistic model, in 
this study, allowed us to identify clones with a contribution 
of at least 5–10% within a given sample. The fact that we 
detected slightly fewer genomic subclones in primary tumors 
than in spheroids and xenografts from the same patient can 
Figure 4. Functional heterogeneity of tcIc 
early and late in serial transplantation. 
(A) Tumor cells of early and late xenograft 
tumors, used for assessing genetic heteroge-
neity by WGS, were genetically barcoded and 
serially transplanted for three mouse genera-
tions. The contribution of individually marked 
cell clones was assessed by LAM-PCR and 
high-throughput sequencing. Relative con-
tribution of individually marked cell clones to 
tumor formation in serial transplantation from 
P1 (B), P2 (C), and P3 (D). Each row displays 
one unique IS; each column displays one xe-
nograft in serial transplantation. Dotted lines, 
2° n/a. Arrows indicate serial transplantation 
steps. (E) Total number of ISs detected in se-
rial transplants derived from X1 or X2 and 
corresponding mean GFP expression (green). 
(F) Relative contribution of functional tu-
mor-initiating cell classes to early and late TcIC 
compartments in individual xenografts, and 
(G) on average, from three patients. Error bars 
represent the SEM. (A–G) All experiments were 
performed independently with tumor material 
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likely be attributed to the lower tumor cell content in pa-
tient tumors. Selective engraftment of subclonal tumor-cell 
populations in xenograft and in vitro models points to initial 
seeding efficiency as a major bottleneck for studying sub-
clone composition in experimental models (Klco et al., 2014; 
Eirew et al., 2015; van de Wetering et al., 2015). Notably, in 
our study, a single-cell suspension was prepared from P1 pri-
mary tumor cells, and equal proportions of cells were used for 
spheroid culture and xenotransplantation and tumor sequenc-
ing. In contrast, sequencing of P2 and P3 patient tumor tissue 
and the generation of serial samples were performed from 
independently sampled tumor pieces of the same patient’s 
tumor. Regional differences in subclone composition in the 
patient tumor (Sottoriva et al., 2015) sampled for tumor tissue 
sequencing and generation of spheroids most likely contrib-
uted to the increased mutational differences among primary 
tumors and the derived serial samples in our setting.
In agreement with our results, coexistence of multiple 
genetic subclones and variation of genetic subclones in pa-
tient-derived organoid models and xenografts have previously 
been observed in solid cancer tumors and other entities (An-
derson et al., 2011; Schmitz et al., 2011; Klco et al., 2014; 
van de Wetering et al., 2015), which raises the question of 
whether specific genetic events pivotally fuel the proliferation 
and survival of individual subclones. Interestingly, we found 
only a few mutations in commonly mutated CRC genes or 
in genes involved in DNA MMR pathways attributable to 
subclonal SNV populations. Private point mutations pres-
ent in individual growth clones in relevant genes, including 
β-catenin or APC, in our study, point toward a functional 
role for those private mutations in the development of in-
dividual genomic subclones. The functional effect of those 
mutations, however, needs to be addressed in future studies. 
The majority of the tested potential driver SNVs were fully 
clonal, which is in line with recent multiregion sequencing 
studies, indicating that most common mutations in CRCs are 
shared throughout all sites and are most probably acquired 
early during cancer progression (Jesinghaus et al., 2015; Kim 
et al., 2015; Sottoriva et al., 2015). Interestingly, in our study, 
different genomic subclones dominated in vitro cultures or 
in vivo xenografts. This may be a consequence of different 
environmental conditions, including oxygen levels, anchor-
age-independent growth, and other microenvironmental fac-
tors, and opens up an avenue for studying the impact of such 
factors on subclone dynamics in controlled models (Visvader 
and Lindeman, 2012; Weiswald et al., 2015).
Two limitations of our study need to be considered. 
First, our experimental approach required transplantation of 
human CRC cells under the kidney capsule of highly im-
mune-deficient NSG mice. We and others have previously 
shown that this strategy allows highly efficient engraftment 
of primary patient tumor cells (O’Brien et al., 2007; Ric-
ci-Vitiani et al., 2007; Dieter et al., 2011). We did not trans-
plant orthotopically due to the requirement to transplant 
large numbers of tumor cells to allow for representative and 
sensitive genetic subclone detection, which is not feasible at 
orthotopic locations. Orthotopic transplantation of CRC 
cells may, in theory, provide a more-physiological environ-
ment, even though that has not been proven experimentally. 
Moreover, the role of the immune system cannot be assessed 
in experimental models that allow in vivo tumor formation 
by human cancer cells because of the immunosuppression re-
quired. Further, the disruption of the original tumor architec-
ture, as well as the transplantation of human tumor cells into 
a xenogenic environment, may influence the behavior of the 
assayed tumor-cell population. Second, our study was done 
with the limited number of three CRC samples. The results 
observed were very similar among those patients, irrespective 
of whether primary tumor– or metastasis-derived tissue was 
analyzed, indicating that our results are at least applicable to a 
large proportion of CRCs.
Considering the number of cells used in our study in 
comparison to the overall cell load of a patient’s tumor, many 
genomic subclones presumably coexist in a patient’s tumor at 
the time of diagnosis. Consequently, sequential therapy or in-
termittent drug schedules may cause profound subclone dy-
namics because of dynamic-adaptation processes (Siravegna 
et al., 2015). Because functional and genetic heterogeneity 
within the TcIC compartment is reflected in patient-derived 
xenografts and TcIC-enriched spheroids, they represent suit-
able models for identifying subclone selection and the de 
novo alterations underlying therapy sensitivity and resistance.
In conclusion, in this study, we demonstrated that, in 
CRC, multiple subclones drive long-term tumor formation. 
Individual subclones can grow out during serial in vitro and 
in vivo passaging, and within the same patient, the domi-
nating subclones in the xenografts and spheroids can differ. 
Strikingly, functional differences and genetic-clone diversity 
are two independent layers of heterogeneity within individual 
CRC tumors that need to be addressed therapeutically to 
overcome treatment resistance.
These findings have important implications for 
the development and design of future studies target-
ing tumorigenic CRC cells.
MAterIALS And MethodS
Isolation and culture of crc cells
All experiments with human material were performed in ac-
cordance with the guidelines of the Declaration of Helsinki 
and were approved by the ethics committee of the Medical 
Faculty at the University Heidelberg (323/2004). Informed 
consent was received from participants before study inclu-
sion. Representative pieces of tumor tissue and matching 
normal control (P1, whole blood; P2 and P3, normal in-
testinal mucosa) were collected from patients undergoing 
surgery at the Department of Surgery, University Hospital 
(Heidelberg, Germany), and representative pieces were fro-
zen at −80°C for histologic assessment. To obtain single-cell 
suspensions, tumor tissue was cut into 2–3-mm, small pieces 
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magnesium chloride, supplemented with 1% antibiotic–
antimycotic in a rotating incubator for 1.5 h at 37°C. Di-
gested cells were filtered, washed, and cultured in advanced 
DMEM/F-12 (Gibco/Invitrogen), supplemented with 0.6% 
glucose, 2 mM PenStrep, and 2 mM l-glutamine (all Invit-
rogen); 4 µg/ml heparin, 5 mM Hepes, and 4 mg/ml BSA 
(all Sigma-Aldrich); and 10 ng/ml human fibroblast growth 
factor and 20 ng/ml epidermal growth factor (R&D Sys-
tems) in ultralow attachment flasks (Corning). For each pa-
tient, spheroid cultures were established and seeded for serial 
passaging (105 cells for P1 and P3 and 2 × 105 cells for P2). 
Spheroid cultures were serially passaged for the entire period 
of serial xenografting (P1, 190 d, equal to ∼16 passages; P2, 
107 d, equal to ∼13 passages; and P3, 142 d, equal to ∼6 
passages), and 6–34% (equal to 5 × 105–1.7 × 107 cells) were 
transferred at each passage step. In total, six spheroid cultures 
were sequenced by WGS (early and late passage cultures for 
3 patients). For P1, the primary tumor sample sequenced 
was obtained from the single-cell suspension, which was also 
used for spheroid formation. From the primary tumors of P2 
and P3, adjacent tumor pieces were used for spheroid-cul-
ture generation or sequencing.
Xenotransplantation
Primary tumor–derived spheroid cells or serial xenograft–
derived, singularized tumor cells were suspended in 50  µl 
culture media, mixed 1:1 with Matrigel (BD), and trans-
planted under the renal capsule of NSG mice (The Jack-
son Laboratory), which were housed under pathogen-free 
conditions, according to the German Animal Protection 
laws and regulations approved by the ethical committee. For 
serial whole-genome sequenced xenografts, 105 cells were 
transplanted into one primary mouse per patient, and after 
xenograft formation, single-cell suspensions were prepared, 
and aliquots were serially transplanted or saved for molecular 
analysis; 13–50% (equal to 1.5 × 106–3.6 × 107) xenograft 
cells were serially transplanted into one secondary and one 
tertiary mouse. In total, six xenografts were whole-genome 
sequenced, i.e., early (first-generation) and late (third-gen-
eration) xenografts for three patients. Because mouse DNA 
lowers the effective sequencing coverage, mouse cells were 
depleted from xenograft tumors by FACS (BD). To that 
end, the xenograft tumors were dissected into a xenograft 
part and a xenograft/kidney-junction zone. Both fractions 
were dissociated and purified separately. The xenograft/kid-
ney-junction fraction was sorted with a human-specific ep-
ithelial cell-adhesion molecule antibody (EBA-1, 1:10; BD). 
The sorted cells were subsequently combined with the sepa-
rately digested cell fraction. For the clonal-marking arms, 105 
transduced cells from the early or late xenograft were initially 
transplanted into one primary mouse per patient; 11–50% 
(equal to 1.3–9 × 106 cells) were serially transplanted for 
three generations. In total, 12 gene-marked xenografts were 
analyzed for P1, 11 xenografts were analyzed for P2, and 12 
xenografts were analyzed for P3.
Library preparation and WGS
DNA was extracted from primary patient tumors, matching 
healthy tissues, serial xenografts, and serial spheroids using 
AllPrep DNA/RNA/miRNA Universal kit (80224; QIA 
GEN). Identity of samples was ensured by ESSplex (QIA GEN) 
analyses. Library preparation was performed with the NEBNext 
DNA Library Prep Master Mix Set (E6040L; Illumina) and 
the NEBNext Multiplex Oligos (set 1 and set 2; E7335S und 
E7500S; Illumina). Library concentrations were measured 
using Qubit 3.0 (Thermo Fisher Scientific), and quality was 
assured with a Bioanalyzer/TapeStation (Agilent Technologies). 
Genomic DNA was sequenced on an HiSeq 2000 (Illumina) 
with 100-bp, paired-end reads (European Genome-Phenome 
Archive; accession no. EGAS00001001857). To decrease 
duplicate rates, three libraries were prepared for each individual 
neoplastic sample and distributed to three to four HiSeq 2000 
lanes each, resulting in 10 lanes per sample, sequenced with 
100-bp paired-end reads. From control samples, one library 
was prepared and sequenced on three lanes. Read pairs were 
mapped to the 1000 Genomes Project phase 2 assembly 
of the human reference genome (hs37d5) using Burrows-
Wheeler Aligner software (version 0.6.2; Li and Durbin, 2009). 
Duplicates were marked with Picard tools (version 1.90, http ://
broadinstitute .github .io /picard /). For alignment of xenograft 
samples, a combined human–mouse reference genome was 
constructed as a concatenation of the 1000 Genomes Project 
phase 2 assembly of the human-reference genome (NCBI 
build 37.1, downloaded from ftp ://ftp .1000genomes .ebi .ac 
.uk /vol1 /ftp /technical /reference /phase2 _reference _assembly 
_sequence /hs37d5 .fa .gz) and the Ensembl version 73 mouse 
reference genome (downloaded from ftp ://ftp .ensembl .org 
/pub /release -73 /fasta /mus _musculus /dna /Mus _musculus 
.GRCm38 .73 .dna .primary _assembly .fa .gz).
SnV identification
Somatic SNVs in tumor, xenograft, and spheroid binary align-
ment/map files were identified using an in-house–developed 
pipeline based on SAMtools mpileup and bcftools (version 
0.1.19, Li et al., 2009) It involves parameter adjustments with 
heuristic filtering to allow calling of somatic variants (Jones 
et al., 2012, 2013). ANN OVAR (Wang et al., 2010) was used 
to annotate the variants with Gencode version 19. Variant al-
lele frequencies (VAFs) of the SNVs were calculated from the 
reference and from alternative read counts of the samtools 
mpileup output. To prevent calling biases in the growth-clone 
analysis, all high-confidence SNVs that were identified in a 
subset of samples from one patient were used as a lookup iden-
tifier in the other samples, using samtools mpileup, and VAFs 
were calculated as described for the directly identified variants.
estimation of cF
The CF of a variant indicates the proportion of tumor cells 
that carry the variant, which can be calculated from the VAF by 
correction for tumor-cell content and regional allele-specific 
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two-step process. First, all VAFs were normalized for tumor-cell 
content. Tumor-cell content was estimated by allele-specific 
copy number estimation from sequencing (ACEseq) analyses 
(described in the Copy number estimation section) as follows: 
P1-TU, 0.55; P1-S1, 1.0; P1-S2, 1.0; P1-X1, 1.0; P1-X2, 1.0; 
P2-TU, 0.88; P2-S1, 1.0; P2-S2, 1.0; P2-X1, 1.0; P2-X2, 1.0; 
P3-TU, 0.55; P3-S1, 1.0; P3-S2, 1.0; P3-X1, 1.0; and P3-X2, 
1.0. Second, the VAFs were corrected for regional copy num-
bers. Only SNVs in regions with clonal copy numbers and 
fewer than four copies in all five samples per patient were con-
sidered for correction. Based on the copy-number state and the 
tumor-cell content-corrected VAF, it was estimated whether an 
SNV was most likely found on one, two, or three alleles, i.e., 
variants in diploid regions with corrected VAFs <0.8 were con-
sidered to be present on one allele. In triploid regions, cutoffs 
were set to 0.5 and 0.8 for one and two alleles, respectively. 
VAFs of variants in diploid regions found on one allele (i.e., 
with corrected VAFs <0.8) were multiplied by a factor two. 
Variants in triploid regions found on one allele were multiplied 
by three, whereas variants on two alleles in triploid regions 
required a factor 1.5. Variants in single-copy regions did not 
need further correction.
determination of SnV-based growth clones
Scatterplots of the CFs of pairwise combinations from all 
samples per patient, similar to Fig. 2 A, were used to define 
SNV-based growth clones. A growth clone was defined as a 
distinct cluster of SNVs in those scatterplots. For each patient, 
the main population was defined as the bulk of points dis-
tributed around 1.0 in all samples. Clusters found in a single 
scatterplot were color coded and tracked in all other samples 
for the respective patient. Integration of information from 
scatterplots of other pairwise combinations was used to re-
fine the cluster boundaries and to increase cluster separation. 
SNVs that could not be assigned to any cluster remained in an 
unassigned state (na). One additional growth clone (P1-q4) 
was defined during combinatorics. In that case, two genomic 
subclones (A and B, defined by P1-q1 and P1-q1 + P1-q2) 
could be tracked to the same founder clone, requiring an ad-
ditional growth clone to explain the unique SNVs of one 
of the newly evolved clones (genomic subclone A; see the 
Genomic subclone combinatorics section). For all SNV-based 
growth clones, the median CF was calculated and rounded to 
the nearest 5% precision.
Supervised analysis of mutational signatures
A supervised analysis of mutational signatures determines 
contributions of known mutational signatures to the muta-
tional catalog, i.e., the counts of the nucleotide exchanges 
in their motif context, of a given data set. As opposed to an 
unsupervised analysis of mutational signatures, i.e., a dis-
covery method such as nonnegative matrix factorization as 
used in (Alexandrov et al., 2013), a supervised analysis re-
quires much less statistical power but will not discover new 
signatures. Software to carry out such an analysis was written 
as an R package (YAP SA [Yet Another Package for Signa-
ture Analysis]). Because of the low requirements on statisti-
cal power, i.e., the number of samples in a cohort and the 
number of point mutations per sample, the supervised analy-
sis of mutational signatures, as performed by YAP SA, may be 
run on very small cohorts.
Using YAP SA, a linear combination decomposition of 
the mutational catalog with known and predefined signatures 
was computed by nonnegative least squares (NNLS), with 
its functions implemented in the R package limSolve (Van 
Den Meersche et al., 2009). To increase specificity, the NNLS 
algorithm was applied twice: once proposing all signatures 
supplied by the user to the decomposition, and then, after 
the first execution, only those signatures with exposures 
(i.e., contributions in the linear combination) greater than a 
certain cutoff were kept, and the NNLS was run again with 
the reduced set of signatures. Because detectability of the 
different signatures can vary, signature-specific cutoffs were 
chosen, as determined in a receiver operating characteristic 
analysis from publicly available data on mutational catalogs 
of 7,042 cancers (507 from WGS and 6,535 from whole-
exome sequencing; Alexandrov et al., 2013) and mutational 
signatures (http ://cancer .sanger .ac .uk /cosmic /signatures). 
Before running an analysis, YAP SA builds up the mutational 
catalogs of the samples or cohorts to be analyzed by calling 
the functions mutationContext and mutationContextMatrix 
from the R package SomaticSignatures (Gehring et al., 2015).
YAP SA was used to stratify the analysis of mutational 
signatures. For each patient, the growth clones (as defined 
in the section Genomic subclones are highly dynamic in 
spheroids and xenografts) were taken as strata. The stratified 
analysis was performed as a multistep procedure: (1) to de-
termine which mutational signatures were present in the 
sample, the supervised analysis of mutational signatures was 
first run (as described in Genomic subclones harbor distinct 
mutational signatures section) without any stratification; (2) 
for every detected SNV in a sample, the stratum it belonged 
to (i.e., the growth clone, as determined by an analysis of CFs 
as described in Genomic subclones are highly dynamic in 
spheroids and xenografts section) was annotated in the ini-
tial variant-calling file (vcf-like); (3) for every stratum, a stra-
tum-specific mutational catalog was built (as described in the 
Supervised analysis of mutational signatures section); and (4) 
enrichment and depletion patterns for all mutational signa-
tures detected in step 1 were computed from the mutational 
catalogs of all strata. Step 4, implemented in YAP SA, involved 
a supervised and constrained analysis of mutational signatures, 
performed by constrained NNLS, also using limSolve (Van 
Den Meersche et al., 2009), with the constraint as the sum 
over the strata of exposures per stratum equaling the expo-
sures computed by the unstratified analysis.
To obtain characteristic enrichment and depletion pat-
terns per signature, cohort-wide averages per stratum over the 
sample-wise exposures were computed. Differences among 
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multiple testing with the Benjamini-Hochberg procedure 
(P1: AC1, p = 1.331 × 10−4, AC6, p = 1.586 × 10−4, AC15, 
p = 1.586 × 10−4, AC17, p = 1.586 × 10−4, and AC26, p = 
6.680 × 10−3; P2: AC1, 1.416 × 10−3, AC3, 2.611 × 10−3, 
AC9, 2.626 × 10−3, AC13, 1.416 × 10−3, and AC17, 1.416 × 
10−3; and P3: AC1, 3.408 × 10−2, AC3, 3.408 × 10−2, AC8, 
5.125 × 10−2, AC9, 5.125 × 10−2, AC13, 4.019 × 10−2, and 
AC15, 3.112 × 10−1). Absolute and relative exposures per 
sample and per stratum as well as cohort-wide averages were 
displayed in integrative figures.
driver- and signature-related genes
Commonly mutated genes in CRC were defined from The 
Cancer Genome Atlas (Cancer Genome Atlas Network, 
2012), MMR, and DSB homologous recombination or DSB 
nonhomologous end-joining from the Kyoto Encyclopedia 
of Genes and Genomes (KEGG; hsa03440, hsa03450, and 
hsa03430; Kanehisa and Goto, 2000; Kanehisa et al., 2016) 
and the Gene Ontology (GO; GO0000724, GO0006303, 
and GO0006298; Ashburner et al., 2000; Gene Ontology 
Consortium, 2015) databases. Variants were annotated with 
Combined Annotation-Dependent Depletion scores (version 
1.3; Kircher et al., 2014).
Structural variant calling
The CRE ST algorithm (Wang et al., 2011), with default 
parameters, was used to call structural variants from the 
primary alignment data.
copy number estimation
Copy numbers were estimated using ACEseq. This method 
uses a coverage ratio of tumor and control over genome 
windows as well as the B-allele frequency (BAF). In addition 
to the copy numbers, tumor ploidy and tumor-cell content 
were estimated in ACEseq. During preprocessing of the data, 
allele frequencies were obtained for all single-nucleotide 
polymorphism (SNP) positions recorded in the dbSNP 
database (Database of Single Nucleotide Polymorphisms 
[dbSNP]. Bethesda [MD]: National Center for Biotechnology 
Information, National Library of Medicine. [dbSNP Build ID: 
135]. Available from: http ://www .ncbi .nlm .nih .gov /SNP /). 
To improve sensitivity for unbalanced and balanced regions, 
SNP positions in the control were phased with impute2 
(Howie et al., 2009). Additionally, the coverage for 10 kbp 
windows with sufficient mapping quality and read density was 
recorded and subsequently corrected for guanine-cytosine 
content and replication timing to remove coverage changes 
introduced by those biases.
The genome was segmented using the PSC BS pack-
age in R software (Olshen et al., 2011) in consideration of 
structural-variant breakpoints defined by CRE ST. Segments 
were clustered, using k-means clustering, according to their 
coverage ratio and BAF value, and neighboring segments 
that fell into the same cluster were joined. Small segments 
(<9 kbp) were attached to the more-similar neighbor. Fi-
nally, tumor-cell content and the ploidy of the samples were 
estimated by testing how well different tumor-cell content 
and ploidy combinations explained the data. Segments with 
balanced BAF were fitted to even-numbered copy-number 
states, whereas unbalanced segments were allowed to fit to 
uneven numbers as well. Finally, estimated tumor-cell con-
tent and ploidy values were used to compute the total and 
allele-specific copy number for each segment.
The coverage for the control of P3 was very noisy and 
prevented a proper estimation of the copy number states. 
Thus, the 10-kbp control coverage used to obtain the cov-
erage ratio was replaced by an unmatched in-house control. 
Heterozygous SNPs for BAF estimation were obtained from 
the original patient control.
For P1-S1, a tetraploid solution allowed a slightly bet-
ter fit of the segments than a diploid solution did. However, 
because all other samples for that patient were estimated 
to be diploid and the SNV mutant-allele frequency distri-
bution does not support tetraploidy, the ploidy for P1-S1 
was adjusted accordingly.
determination of cnA-based growth clones
Genomic segments with indications for subclonal copy num-
ber aberrations were used to define CNA-based growth 
clones. For this, segments ≥2.5 Mbp with noninteger copy 
numbers (>30% deviation from the nearest integer copy 
number) in at least one sample were determined systemati-
cally. Interruptions <10 kbp were ignored, and segments with 
two noninteger alleles were excluded. For all remaining seg-
ments, genomic breakpoints were extracted. Exact copy num-
bers were calculated as the mean copy number of all SNPs 
in a respective region. CFs for the underlying growth clones 
were estimated for each segment using a minimalistic model 
with two contributing growth clones differing by a single 
copy number. Values were rounded to the nearest 10%. Seg-
ments with similar CF dynamics over time (deviations ≤10%) 
were assigned to the same growth clone. In those cases, the 
CF found in the majority of segments of one growth clone 
was used for the genomic subclone combinatorics. In cases 
with equal numbers of segments displaying two different CFs, 
a CF range was used for genomic subclone combinatorics.
Genomic subclone combinatorics
Genomic subclone combinatorics was used to assign SNV- 
and CNA-based growth clones to—and thus identify the 
minimal number of—distinct genomic subclones. The CF was 
used as the common denominator, and maximum parsimony 
was applied for the construction of the phylogenetic trees.
Patient 1. In the primary tumor of P1, two growth clones 
(P1-q1 and P1-q3) were easily identifiable. P1-q1 was as-
signed to genomic subclone A (Fig. S2 A, dark green) and 
P1-q3 to genomic subclone C (Fig. S2 A, orange). P1-q2 was 
first identified in S1. Because P1-q1 and P1-q2 displayed col-
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growth clones was concluded. In S1, P1-q1 and P1-q2 were, 
therefore, combined in genomic subclone B with 5% (Fig. S3 
A, light blue). In addition, a remaining fraction of P1-q1 was 
assigned to genomic subclone A. P1-q4 resulted as a logical 
consequence from the branching of q1 into genomic sub-
clones A and B. SNVs in P1-q1 must represent SNVs present 
in the founder clone, whereas P1-q2 comprised SNVs present 
in an individual clone. The vast number of SNVs in P1-q2 
suggested that the separation from its ancestor P1-q1 hap-
pened a considerable phylogenetic time ago. Thus, we ex-
pected an additional SNV growth clone contributing to 
genomic subclone A, explaining the difference between CFs 
of P1-q1 and P1-q2. That growth clone was defined by the 
difference of CFs in S1 (40%) and X1 (30%) and fulfilled the 
condition of disappearing in X2 because P1-q2 was as prom-
inent as P1-q1, without adding that constraint in the first 
definition. Genomic subclone C contributed to 20% in S1. 
The previously undetected growth clone P1-c1 was assigned 
to genomic subclone D, contributing 10% (Fig. S2 A, purple). 
In Fig. S2, P1-q3 and P1-q5 were assigned to genomic sub-
clone E with 90–95% CF (Fig. S2 A, light green). In X1 and 
X2, all growth clones could be explained with previously de-
termined genomic subclones.
Patient 2. All cells in the primary tumor of P2 comprised 
P2-c2 and P2-c3. In addition, growth clones P2-c5 and P2-c6 
were present in TU with a CF of 40 and 50%, respectively. 
Both were assigned to genomic subclone A (Fig. S2 B, dark 
green). Genomic subclone B (Fig. S2 B, light blue) was de-
fined by the remaining CFs of P2-c2 and P2-c3. In S1, two 
SNV-based growth clones were detected (P2-q1 and P2-q3). 
P2-q1 was present with 10% CF and, therefore, was com-
bined with the CNA-based growth clone P2-c3 (also 10% 
CF) and was assigned to growth clone C (Fig. S2 B, orange). 
Growth clone P2-q3 was assigned to the independent ge-
nomic subclone D (Fig. S2 B, purple). The independence of 
P2-q1 and P2-q3 was substantiated by the fact that, in X1 and 
X2, P2-q1 contributed substantially more than P2-q3, and in 
S1 and S2, P2-q3 displayed more CF than P2-q1 had. In a 
model with one genomic subclone harboring both growth 
clones, the fractions P2-q1 and P2-q3 should be always pres-
ent with the same CF. In the case of one ancestor and a sec-
ond, further-developed genomic subclone, ancestral SNVs 
should be equal or greater in all samples. P2-c1 and P2-c2 
were present with 60–70% CF in S1 and, therefore, were as-
signed to genomic subclone E (Fig. S2 B, light green). An 
ancestral connection of genomic subclone B and genomic 
subclone C, as well as genomic subclone B and genomic sub-
clone E with shared CNAs, would have been possible theo-
retically. Because of the sampling strategy in P2 (adjacent 
tumor pieces for sequencing and spheroid culture genera-
tion), a model with independent genomic subclones was cho-
sen. That decision was supported by the general absence of 
shared SNV-based growth clones between TU and the re-
maining samples in this patient and, importantly, did not in-
fluence the total number of genomic subclones in those 
samples. In S2, all growth clones could be explained with 
previously defined genomic subclones. In X1, P2-c4 was de-
tected with 10%. In X2, CFs of P2-q1 and P2-c3 increased to 
90% and P2-c4 to 60%, clearly indicating partial dependence 
by those growth clones. In X1, P2-c4 was, therefore, assigned 
to genomic subclone F (Fig. S2 B, dark blue), branching from 
genomic subclone C, thus, also containing P2-q1 and P2-c3. 
All remaining genomic subpopulations could be explained 
with previously defined genomic subclones. In X2, the previ-
ously undetected growth clone P2-q2 was detected at CFs of 
60% and was, therefore, coassigned with P2-q1, P2-c3, and 
P2-c4 to genomic subclone G (Fig. S2 B, red), branching 
from genomic subclone F. Further, growth clone P2-c1 was 
assigned to genomic subclone H (Fig. S2 B, brown), poten-
tially descending from genomic subclone E.
Patient 3. In the primary tumor of P3, all cells harbored 
P3-c5. In addition, P3-c1 and P3-c3 were present with 20–
30% CF and were assigned to genomic subclone A (Fig. S2 C, 
dark green). Genomic subclone B harbored P3-c2 and P3-c5 
(Fig. S2 C, light blue). P3-c4, which was present with 70% CF, 
could be assigned to subclones A and B. Genomic subclone C 
(Fig. S2 C, orange) harbored P3-c5 and P3-c6. In S1, P3-q1 
and P3-c3 were assigned to genomic subclone D (Fig. S2 C, 
purple) based on concordant CFs. Two further genomic sub-
clones were necessary to explain the remaining growth clones 
(P3-q2, P3-c4, and P3-c5). P3-q2 was assigned to subclone E 
(Fig. S2 C, light green) and P3-c5 to subclone F (Fig. S2 C, 
dark blue), both harboring P3-c4, therefore descending from 
a common ancestor. For the same reasons explained for P2, a 
model with independent genomic subclones from P3-TU to 
P3-S1 was chosen. In S2, a previously undetected growth 
clone, P3-q3, together with P3-c6, was detected at a cellular 
fraction of 60–65% and was assigned to genomic subclone H 
(Fig. S2 C, brown), a descendant from genomic subclone E. In 
X1, all growth clones could be explained with previously 
identified genomic subclones. In X2, the strong outgrowth of 
P3-q1 required a genomic subclone purely containing that 
growth clone (Fig. S2 C, red) and was possibly a descendant 
from genomic subclone D.
Genetic marking of crc cells
An enhanced GFP–expressing. vesicular stomatis virus pro-
tein G–pseudotyped, third-generation, self-inactivating lenti-
viral vector, under the control of the human CMV promoter, 
was produced (Dull et al., 1998) and concentrated through 
ultracentrifugation. Polyethylenimine (Sigma-Aldrich) was 
used for the stable genetic marking of CRC cells at multi-
plicities of infection of 20–30. To that end, dissociated colon 
cancer cells were transduced with Viromag R/L beads (OZ 
Biosciences), with transduction efficiencies ranging from 1 to 
80%. To assess lentiviral IS, 3′-LAM-PCR was performed and 
analyzed, as described, using the restriction enzyme MluCI 
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justed for downstream Illumina sequencing. Raw LAM 
amplicon sequences were trimmed, aligned to the human ge-
nome assembly (GRCh38/hg38), and clustered.
online supplemental material
Fig. S1 presents the genome-wide distribution of SNVs, and 
Fig. S2 shows a detailed model of growth clones. Fig. S3 pro-
vides mutational signatures for all SNV-based growth clones, 
and Table S1 (in a separate Excel file) presents mutations in 
CRC-associated and MMR genes.
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